What the Options Market Tells Us About Amgen
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.
金融巨頭在安進上做出了明顯的看淡動作。我們對安進（納斯達克：AMGN）期權歷史的分析顯示，有9筆異常交易。
Delving into the details, we found 11% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $169,060, and 6 were calls, valued at $411,757.
深入細節後，我們發現有11%的交易者看好，而55%的交易者表現出看淡趨勢。在我們發現的所有交易中，有3筆看跌期權，價值爲169,060美元，有6筆看漲期權，價值爲411,757美元。
What's The Price Target?
價格目標是什麼？
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $305.0 to $330.0 for Amgen during the past quarter.
分析這些合約的成交量和未平倉量，似乎大佬們一直在關注安進在過去的季度內的$305.0至$330.0的價格區間。
Volume & Open Interest Trends
成交量和未平倉量趨勢
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Amgen's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Amgen's significant trades, within a strike price range of $305.0 to $330.0, over the past month.
仔細審視成交量和未平倉量，能爲股票研究提供重要的見解。這些信息對於衡量在特定行使價格下，對安進期權的流動性和興趣水平至關重要。以下是我們在去過的一個月中，以$305.0至$330.0行使價格區間內安進的看漲期權和看跌期權成交量和未平倉量趨勢的快照。
Amgen Option Volume And Open Interest Over Last 30 Days
安進期權成交量和未平倉量在過去30天內的情況
Significant Options Trades Detected:
檢測到重大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | TRADE | NEUTRAL | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 262 |
| AMGN | CALL | TRADE | NEUTRAL | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 112 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $74.5K | 163 | 62 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $15.1 | $14.7 | $14.85 | $305.00 | $72.7K | 163 | 212 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $71.5K | 163 | 14 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看漲 | 交易 | 中立 | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 262 |
| AMGN | 看漲 | 交易 | 中立 | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 112 |
| AMGN | 看漲 | 交易 | 看淡 | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $74.5K | 163 | 62 |
| AMGN | 看漲 | 交易 | 看淡 | 08/16/24 | $15.1 | $14.7 | $14.85 | $305.00 | $72.7K | 163 | 212 |
| AMGN | 看漲 | 交易 | 看淡 | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $71.5千美元 | 163 | 14 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
在我們分析與安進相關的期權活動之後，我們將轉向更仔細地研究公司自身的表現。
Where Is Amgen Standing Right Now?
目前安進的處境如何？
- Currently trading with a volume of 818,723, the AMGN's price is down by -0.29%, now at $310.12.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 30 days.
- 目前成交量爲818,723，安進的價格下跌了-0.29%，現在爲310.12美元。
- RSI讀數表明該股目前可能接近超買水平。
- 預計收益發布還需30天。
Professional Analyst Ratings for Amgen
安進的專業分析師評級
2 market experts have recently issued ratings for this stock, with a consensus target price of $336.0.
2位市場專家最近對這支股票發表了評級，共識目標價爲336.0美元。
- An analyst from RBC Capital has decided to maintain their Outperform rating on Amgen, which currently sits at a price target of $332.
- Maintaining their stance, an analyst from Argus Research continues to hold a Buy rating for Amgen, targeting a price of $340.
- 摩根資本（RBC Capital）的一位分析師決定維持對安進的跑贏大盤評級，目前的股價目標爲332美元。
- 維持他們的立場，雅運股份分析師繼續對安進持有買入評級，目標價爲340美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期權交易具有更高的風險和潛在回報。精明的交易者通過不斷學習、調整策略、監控多個因子和密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時提醒了解最新的安進期權交易。
譯文內容由第三人軟體翻譯。